Symbol="FATE"
AssetType="Common Stock"
Name="Fate Therapeutics Inc"
Description="Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California."
CIK="1434316"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="259219000"
EBITDA="-225275008"
PERatio="None"
PEGRatio="0"
BookValue="4.443"
DividendPerShare="0"
DividendYield="0"
EPS="-2.09"
RevenuePerShareTTM="1.221"
ProfitMargin="-1.774"
OperatingMarginTTM="-2.029"
ReturnOnAssetsTTM="-0.217"
ReturnOnEquityTTM="-0.415"
RevenueTTM="119250000"
GrossProfitTTM="-224154000"
DilutedEPSTTM="-2.09"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.95"
AnalystTargetPrice="7.24"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.01"
PriceToBookRatio="2.883"
EVToRevenue="15.93"
EVToEBITDA="-3.697"
Beta="1.461"
num_52WeekHigh="29.42"
num_52WeekLow="2.5"
num_50DayMovingAverage="4.181"
num_200DayMovingAverage="7.54"
SharesOutstanding="98562000"
DividendDate="None"
ExDividendDate="None"
symbol="FATE"
open="2.56"
high="2.67"
low="2.50"
price="2.63"
volume="1736336.00"
latest_trading_day="2023-08-25"
previous_close="2.56"
change="0.07"
change_percent="2.7344%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="2250894"
Change_recent_avg="-0.04"
Delta_recent_avg="0.31"
Variance_recent_avg="0.16"
Change_ratio_recent_avg="-0.96"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="1093"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0126.jpeg"
image_negative_thumbnail_id_2="1123"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0156.jpeg"
image_neutral_thumbnail_id_1="587"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_neutral_thumbnail_id_2="566"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_positive_thumbnail_id_1="1002"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0164.jpeg"
image_positive_thumbnail_id_2="670"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0038.jpeg"
image_professor_thumbnail_id_1="1191"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
